AURORA KINASE A and related downstream molecules: A potential network for cancer therapy

Adv Protein Chem Struct Biol. 2023:134:115-145. doi: 10.1016/bs.apcsb.2022.10.005. Epub 2023 Jan 31.

Abstract

Aurora-A kinase (AURKA) belongs to the serine/threonine kinase family specific to cell division. In normal cells, activation of the AURKA protein is essential for regulating chromosomal segregation and centrosome maturation. The physiological concentration of AURKA accumulation has utmost importance during cell division. AURKA starts accumulating during the S phase of the cell cycle, gets functionally activated during the G2/M phase, attaches to the microtubule, and gets degraded during mitotic exit. Overexpression of AURKA could lead to deregulated cell cycle division, which is intrinsic to numerous cancers. Moreover, dysregulated AURKA affects various downstream molecules that aid in cancer pathogenesis. AURKA phosphorylates its substrates, including oncoproteins, transcriptional factors, tumor suppressor proteins, or other kinases central to various oncogenic signaling pathways critical to cancer. Considering the central role of AURKA in cell proliferation and tumorigenesis, targeting AURKA can be a novel alternative to cancer management. Several AURKA inhibitors have shown promising responses against different cancers either as a single agent or combined with various therapies. This chapter briefly discusses the role of AURKA and its downstream molecules in cancer vis-à-vis the role of AURKA inhibitor in chemoprevention.

Keywords: AURKA; Cancer; Cell cycle; Downstream targets; Signaling molecules; Therapy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aurora Kinase A*
  • Carcinogenesis*
  • Cell Cycle
  • Cell Proliferation
  • Humans
  • Protein Kinase Inhibitors

Substances

  • Aurora Kinase A
  • Protein Kinase Inhibitors